(Drug Name) (Drug Form) (Drug Strength)
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Interferon Beta-1b: Lyophilisate for solution for injection (0.3mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

INTERFERON BETA-1b (in ter FEER on BAY ta 1b) helps to decrease the number of multiple sclerosis attacks in people with relapsing forms of the disease. This medicine does not cure multiple sclerosis.

In-Depth Information

Extavia 0.3mg Powder for Injection

NDC: 000780569
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Multiple Sclerosis

Storage Information
Discard unused portion. Do not store for later use.
Protect from freezing
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Reconstituted product should be refrigerated and used within 3 hours if not used immediately
Extavia 0.3mg Powder for Injection

Reported Side Effects for Extavia 0.3mg Powder for Injection

Muscle Cramps Incidence:
<2.0%*
Severity: MILD
Onset: DELAYED
Lightheadedness Incidence:
<2.0%*
Severity: MILD
Onset: EARLY
Heavy Menstrual Period Incidence:
<2.0%*
Severity: MILD
Onset: DELAYED
Muscle Weakness Incidence:
<2.0%*
Severity: MODERATE
Onset: DELAYED
Rapid Heart Rate Incidence:
<2.0%*
Severity: MODERATE
Onset: EARLY
Peripheral Vasodilation Incidence:
<2.0%*
Severity: MODERATE
Onset: RAPID
Rapid Heart Rate Incidence:
<2.0%*
Severity: MODERATE
Onset: RAPID
Weight Gain Incidence:
<2.0%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
<2.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
<2.0%*
Severity: MILD
Onset: EARLY
Menstrual Cramps Incidence:
<2.0%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
<2.0%*
Severity: MILD
Onset: EARLY
Constipation Incidence:
<2.0%*
Severity: MODERATE
Onset: DELAYED
Joint Pain Incidence:
<2.0%*
Severity: MILD
Onset: DELAYED
Nervousness Incidence:
<2.0%*
Severity: MILD
Onset: DELAYED
Hair Loss Incidence:
<2.0%*
Severity: MILD
Onset: DELAYED
Tissue Death Incidence:
4.0%*
Severity: SEVERE
Onset: EARLY
Elevated Hepatic Enzymes Incidence:
4.0-12.0%*
Severity: MODERATE
Onset: DELAYED
Feeling Sick Incidence:
6.0%*
Severity: MILD
Onset: EARLY
Enlarged Lymph Nodes Incidence:
6.0%*
Severity: MODERATE
Onset: DELAYED
Shortness Of Breath Incidence:
6.0%*
Severity: MODERATE
Onset: EARLY
High Blood Pressure Incidence:
6.0%*
Severity: MODERATE
Onset: EARLY
Impotence (erectile Dysfunction) Incidence:
8.0%*
Severity: MODERATE
Onset: DELAYED
Chest Pain Incidence:
9.0%*
Severity: MODERATE
Onset: EARLY
Urinary Urgency Incidence:
11.0%*
Severity: MILD
Onset: EARLY
Irregular Periods Incidence:
12.0%*
Severity: MILD
Onset: DELAYED
Fluid Retention Incidence:
12.0%*
Severity: MODERATE
Onset: DELAYED
Low White Blood Cell Counts Incidence:
13.0-18.0%*
Severity: MODERATE
Onset: DELAYED
Low White Blood Cells Incidence:
13.0%*
Severity: MODERATE
Onset: DELAYED
Stomach Pain Incidence:
16.0%*
Severity: MILD
Onset: EARLY
Antibody Formation Incidence:
16.5-45.0%*
Severity: MODERATE
Onset: DELAYED
Inability To Sleep Incidence:
21.0%*
Severity: MILD
Onset: EARLY
Skin Rash Incidence:
21.0%*
Severity: MILD
Onset: EARLY
Chills Incidence:
21.0%*
Severity: MILD
Onset: RAPID
Muscle Pain Incidence:
23.0%*
Severity: MILD
Onset: EARLY
Depression Incidence:
30.0%*
Severity: MODERATE
Onset: DELAYED
Fever Incidence:
31.0%*
Severity: MILD
Onset: EARLY
Injection Site Reaction Incidence:
40.0-78.0%*
Severity: MILD
Onset: RAPID
Excessive Mucle Tone Incidence:
40.0%*
Severity: MODERATE
Onset: DELAYED
Headache Incidence:
50.0%*
Severity: MILD
Onset: EARLY
Weakness Incidence:
53.0%*
Severity: MILD
Onset: DELAYED
Low Lymphocytes Incidence:
86.0%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Interferon Beta-1b

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5